0001127602-13-017602.txt : 20130520 0001127602-13-017602.hdr.sgml : 20130520 20130520191554 ACCESSION NUMBER: 0001127602-13-017602 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130517 FILED AS OF DATE: 20130520 DATE AS OF CHANGE: 20130520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON REBECCA M CENTRAL INDEX KEY: 0001254748 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12477 FILM NUMBER: 13859883 MAIL ADDRESS: STREET 1: IDEXX LABORATORIES INC STREET 2: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2013-05-17 0000318154 AMGEN INC AMGN 0001254748 HENDERSON REBECCA M ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 1 Common Stock 2013-05-17 4 M 0 2000 58.43 A 8898 D Common Stock 2013-05-17 4 M 0 5000 54.69 A 13898 D Common Stock 2013-05-17 4 S 0 7000 105.6994 D 6898 D Common Stock 2013-05-17 4 S 0 1421 105.8441 D 5477 D Nqso (Right to Buy) 58.43 2013-05-17 4 M 0 2000 0 D 2011-04-26 2020-04-26 Common Stock 2000 3000 D Nqso (Right to Buy) 54.69 2013-05-17 4 M 0 5000 0 D 2012-04-25 2021-04-25 Common Stock 5000 0 D The price reported is an average price. The prices ranged from $105.67 to $105.75 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. The price reported is an average price. The prices ranged from $105.8301 to $105.85 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. /s/ Andrea Robinson, Attorney-in-Fact for Dr. Henderson 2013-05-20